UroGen Pharma (URGN) PT Lowered to $34 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Price: $34.34 +0.88%
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Rating Summary:
10 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 17 | New: 16
Join SI Premium – FREE
Oppenheimer analyst Leland Gershell lowered the price target on UroGen Pharma (NASDAQ: URGN) to $34.00 (from $40.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- JPMorgan Assumes Airtac International (1590:TT) at Overweight
- FireFly Metals Ltd (FFM:AU) PT Raised to AUD3.60 at Canaccord
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
